Pre-Surgical Window of opportunity trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer
Sponsor: |
Breast Cancer Research Foundation Grant |
Enrolling: |
Female Patients Only |
IRB Number: |
AAAM2306 |
U.S. Govt. ID: |
NCT01980823 |
Contact: |
Kevin Kalinsky, MD, MS: 212-305-0170 / kk2693@cumc.columbia.edu |
The purpose of this study is to determine the effects of combining metformin and atorvastatin treatment in patients with newly diagnosed breast cancer during the interval between breast biopsy and surgery. Metformin is a common treatment for patients with diabetes, and atorvastatin is a common therapy for elevated cholesterol. We will examine the effects of the combination of metformin plus atorvastatin on changes in breast tumor tissue as well as various blood levels, including insulin and cholesterol levels. The combination of metformin and atorvastin is an experimental treatment for your condition.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Have you been diagnosed with invasive breast cancer? |
Yes |
No |
Have you had chemotherapy, radiation therapy, or breast resection in the last 6 months? |
Yes |
No |